File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes
  • Basic View
  • Metadata View
  • XML View
TitleBroad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes
 
AuthorsChen, Y1 2
Qin, K2
Wu, WL
Li, G1
Zhang, J1
Du, H1
Ng, MH
Shih, JWK1
Peiris, JSM2
Guan, Y2 3
Chen, H2 3
Xia, N1
 
Issue Date2009
 
PublisherOxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org
 
CitationJournal of Infectious Diseases, 2009, v. 199 n. 1, p. 49-58 [How to Cite?]
DOI: http://dx.doi.org/10.1086/594374
 
AbstractBackground. Passive immunization with human H5 antisera or H5-specific monoclonal antibodies (MAbs) has potential as an effective treatment for acute H5N1 influenza virus infection, but its efficacy against antigenically diverse H5N1 viruses is unconfirmed. Methods. Cross-protection against antigenically diverse H5N1 strains with H5-specific MAbs, generated by successive immunization of antigenically distinct strains, was evaluated in mice. Results. A panel of 52 broadly cross-reactive H5 specific MAbs were generated and characterized. One of these MAbs, 13D4, has been demonstrated to protect mice against lethal challenge by 4 H5N1 strains representing the current major genetic populations, clades 1, 2.1, 2.2, and 2.3, even at a stage of infection when H5N1 virus has disseminated beyond the pulmonary system. Complete neutralization of virus in lung tissue of infected animals was observed 24 h after treatment with 13D4. Mapping of this MAb with escape mutants showed it to bind to 2 conserved, possibly critical, sites of H5N1 hemagglutinin, 152 and 182. Conclusion. Generation of broadly cross-protective MAbs against H5N1 influenza virus may be optimized by selecting MAbs that target conserved sites in hemagglutinin. H5 MAbs such as 13D4 may prove to have therapeutic value in controlling infection due to current and future H5N1 variants. © 2008 by the Infectious Diseases Society of America. All rights reserved.
 
ISSN0022-1899
2012 Impact Factor: 5.848
2012 SCImago Journal Rankings: 2.723
 
DOIhttp://dx.doi.org/10.1086/594374
 
ISI Accession Number IDWOS:000261754400008
 
ReferencesReferences in Scopus
 
DC FieldValue
dc.contributor.authorChen, Y
 
dc.contributor.authorQin, K
 
dc.contributor.authorWu, WL
 
dc.contributor.authorLi, G
 
dc.contributor.authorZhang, J
 
dc.contributor.authorDu, H
 
dc.contributor.authorNg, MH
 
dc.contributor.authorShih, JWK
 
dc.contributor.authorPeiris, JSM
 
dc.contributor.authorGuan, Y
 
dc.contributor.authorChen, H
 
dc.contributor.authorXia, N
 
dc.date.accessioned2012-08-08T08:51:04Z
 
dc.date.available2012-08-08T08:51:04Z
 
dc.date.issued2009
 
dc.description.abstractBackground. Passive immunization with human H5 antisera or H5-specific monoclonal antibodies (MAbs) has potential as an effective treatment for acute H5N1 influenza virus infection, but its efficacy against antigenically diverse H5N1 viruses is unconfirmed. Methods. Cross-protection against antigenically diverse H5N1 strains with H5-specific MAbs, generated by successive immunization of antigenically distinct strains, was evaluated in mice. Results. A panel of 52 broadly cross-reactive H5 specific MAbs were generated and characterized. One of these MAbs, 13D4, has been demonstrated to protect mice against lethal challenge by 4 H5N1 strains representing the current major genetic populations, clades 1, 2.1, 2.2, and 2.3, even at a stage of infection when H5N1 virus has disseminated beyond the pulmonary system. Complete neutralization of virus in lung tissue of infected animals was observed 24 h after treatment with 13D4. Mapping of this MAb with escape mutants showed it to bind to 2 conserved, possibly critical, sites of H5N1 hemagglutinin, 152 and 182. Conclusion. Generation of broadly cross-protective MAbs against H5N1 influenza virus may be optimized by selecting MAbs that target conserved sites in hemagglutinin. H5 MAbs such as 13D4 may prove to have therapeutic value in controlling infection due to current and future H5N1 variants. © 2008 by the Infectious Diseases Society of America. All rights reserved.
 
dc.description.naturelink_to_OA_fulltext
 
dc.identifier.citationJournal of Infectious Diseases, 2009, v. 199 n. 1, p. 49-58 [How to Cite?]
DOI: http://dx.doi.org/10.1086/594374
 
dc.identifier.citeulike3702994
 
dc.identifier.doihttp://dx.doi.org/10.1086/594374
 
dc.identifier.epage58
 
dc.identifier.hkuros163959
 
dc.identifier.isiWOS:000261754400008
 
dc.identifier.issn0022-1899
2012 Impact Factor: 5.848
2012 SCImago Journal Rankings: 2.723
 
dc.identifier.issue1
 
dc.identifier.pmid19032063
 
dc.identifier.scopuseid_2-s2.0-58749101350
 
dc.identifier.spage49
 
dc.identifier.urihttp://hdl.handle.net/10722/157539
 
dc.identifier.volume199
 
dc.languageeng
 
dc.publisherOxford University Press. The Journal's web site is located at http://jid.oxfordjournals.org
 
dc.publisher.placeUnited States
 
dc.relation.ispartofJournal of Infectious Diseases
 
dc.relation.referencesReferences in Scopus
 
dc.subject.meshAnimals
 
dc.subject.meshAntibodies, Monoclonal - Immunology
 
dc.subject.meshBirds - Virology
 
dc.subject.meshBody Weight
 
dc.subject.meshChick Embryo - Virology
 
dc.subject.meshConserved Sequence
 
dc.subject.meshCross Reactions
 
dc.subject.meshEpitopes - Immunology
 
dc.subject.meshHemagglutination Inhibition Tests
 
dc.subject.meshHumans
 
dc.subject.meshInfluenza A Virus, H5N1 Subtype - Classification - Genetics - Immunology - Isolation & Purification
 
dc.subject.meshInfluenza Vaccines - Therapeutic Use
 
dc.subject.meshInfluenza In Birds - Immunology
 
dc.subject.meshInfluenza, Human - Immunology - Mortality - Pathology
 
dc.subject.meshMice
 
dc.subject.meshMice, Inbred Balb C
 
dc.titleBroad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Chen, Y</contributor.author>
<contributor.author>Qin, K</contributor.author>
<contributor.author>Wu, WL</contributor.author>
<contributor.author>Li, G</contributor.author>
<contributor.author>Zhang, J</contributor.author>
<contributor.author>Du, H</contributor.author>
<contributor.author>Ng, MH</contributor.author>
<contributor.author>Shih, JWK</contributor.author>
<contributor.author>Peiris, JSM</contributor.author>
<contributor.author>Guan, Y</contributor.author>
<contributor.author>Chen, H</contributor.author>
<contributor.author>Xia, N</contributor.author>
<date.accessioned>2012-08-08T08:51:04Z</date.accessioned>
<date.available>2012-08-08T08:51:04Z</date.available>
<date.issued>2009</date.issued>
<identifier.citation>Journal of Infectious Diseases, 2009, v. 199 n. 1, p. 49-58</identifier.citation>
<identifier.issn>0022-1899</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/157539</identifier.uri>
<description.abstract>Background. Passive immunization with human H5 antisera or H5-specific monoclonal antibodies (MAbs) has potential as an effective treatment for acute H5N1 influenza virus infection, but its efficacy against antigenically diverse H5N1 viruses is unconfirmed. Methods. Cross-protection against antigenically diverse H5N1 strains with H5-specific MAbs, generated by successive immunization of antigenically distinct strains, was evaluated in mice. Results. A panel of 52 broadly cross-reactive H5 specific MAbs were generated and characterized. One of these MAbs, 13D4, has been demonstrated to protect mice against lethal challenge by 4 H5N1 strains representing the current major genetic populations, clades 1, 2.1, 2.2, and 2.3, even at a stage of infection when H5N1 virus has disseminated beyond the pulmonary system. Complete neutralization of virus in lung tissue of infected animals was observed 24 h after treatment with 13D4. Mapping of this MAb with escape mutants showed it to bind to 2 conserved, possibly critical, sites of H5N1 hemagglutinin, 152 and 182. Conclusion. Generation of broadly cross-protective MAbs against H5N1 influenza virus may be optimized by selecting MAbs that target conserved sites in hemagglutinin. H5 MAbs such as 13D4 may prove to have therapeutic value in controlling infection due to current and future H5N1 variants. &#169; 2008 by the Infectious Diseases Society of America. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Oxford University Press. The Journal&apos;s web site is located at http://jid.oxfordjournals.org</publisher>
<relation.ispartof>Journal of Infectious Diseases</relation.ispartof>
<subject.mesh>Animals</subject.mesh>
<subject.mesh>Antibodies, Monoclonal - Immunology</subject.mesh>
<subject.mesh>Birds - Virology</subject.mesh>
<subject.mesh>Body Weight</subject.mesh>
<subject.mesh>Chick Embryo - Virology</subject.mesh>
<subject.mesh>Conserved Sequence</subject.mesh>
<subject.mesh>Cross Reactions</subject.mesh>
<subject.mesh>Epitopes - Immunology</subject.mesh>
<subject.mesh>Hemagglutination Inhibition Tests</subject.mesh>
<subject.mesh>Humans</subject.mesh>
<subject.mesh>Influenza A Virus, H5N1 Subtype - Classification - Genetics - Immunology - Isolation &amp; Purification</subject.mesh>
<subject.mesh>Influenza Vaccines - Therapeutic Use</subject.mesh>
<subject.mesh>Influenza In Birds - Immunology</subject.mesh>
<subject.mesh>Influenza, Human - Immunology - Mortality - Pathology</subject.mesh>
<subject.mesh>Mice</subject.mesh>
<subject.mesh>Mice, Inbred Balb C</subject.mesh>
<title>Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes</title>
<type>Article</type>
<description.nature>link_to_OA_fulltext</description.nature>
<identifier.doi>10.1086/594374</identifier.doi>
<identifier.pmid>19032063</identifier.pmid>
<identifier.scopus>eid_2-s2.0-58749101350</identifier.scopus>
<identifier.hkuros>163959</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-58749101350&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>199</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>49</identifier.spage>
<identifier.epage>58</identifier.epage>
<identifier.isi>WOS:000261754400008</identifier.isi>
<publisher.place>United States</publisher.place>
<identifier.citeulike>3702994</identifier.citeulike>
<bitstream.url>http://hub.hku.hk/bitstream/10722/157539/1/re01.htm</bitstream.url>
</item>
Author Affiliations
  1. Xiamen University
  2. The University of Hong Kong
  3. Shantou University